A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

NCT06277245 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: LNK01001
DRUG: Placebo

Sponsor

Lynk Pharmaceuticals Co., Ltd